Leukemia/Lymphoma Clinical Trials

1 recruiting

Leukemia/Lymphoma Trials at a Glance

20 actively recruiting trials for leukemia/lymphoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Tianjin, Wuhan, and Suzhou. Lead sponsors running leukemia/lymphoma studies include Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University, and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Browse leukemia/lymphoma trials by phase

Treatments under study

About Leukemia/Lymphoma Clinical Trials

Looking for clinical trials for Leukemia/Lymphoma? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leukemia/Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leukemia/Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1Phase 2

A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

Adult T-Cell Leukemia/Lymphoma (ATLL)
Otsuka Medical Devices Co., Ltd. Japan49 enrolled5 locationsNCT07075328
Recruiting
Phase 2

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
University of Washington33 enrolled1 locationNCT07224100
Recruiting
Phase 1

U69-CART-Cells For R/R T-ALL

Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
The First Affiliated Hospital of Soochow University12 enrolled1 locationNCT07350863
Recruiting
Phase 2

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

LymphomaT-cell LeukemiaT-Cell Leukemia/Lymphoma, Adult+1 more
Memorial Sloan Kettering Cancer Center134 enrolled7 locationsNCT06698003
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+4 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Phase 1

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more
John Reneau12 enrolled1 locationNCT04848064
Recruiting
Phase 2

Venetoclax and Decitabine in R/R T-ALL

T Lymphoblastic Leukemia/Lymphoma
Seoul National University Hospital28 enrolled3 locationsNCT06712121
Recruiting
Phase 1

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Stephan Grupp MD PhD33 enrolled1 locationNCT06934382
Recruiting
Phase 1Phase 2

SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07153068
Recruiting
Phase 2

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting

Novel Therapeutic Approach for Human T-cell Malignancies

T-Cell Leukemia/Lymphoma, Adult
Istituto Oncologico Veneto IRCCS120 enrolled2 locationsNCT06600568
Recruiting
Phase 2

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

Adult T-cell Leukemia/Lymphoma
The First Affiliated Hospital of Soochow University27 enrolled1 locationNCT07159620
Recruiting
Phase 1

uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07109518
Recruiting
Phase 1

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies

Acute Myeloid LeukemiaB Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07106749
Recruiting
Early Phase 1

The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia

B Lymphoblastic Leukemia/Lymphoma
Anhui Provincial Hospital9 enrolled2 locationsNCT06307600
Recruiting
Phase 2

VHAG in Treating R/R T-ALL/LBL

Acute T Lymphpblastic Leukemia/Lymphoma
First Affiliated Hospital of Zhejiang University50 enrolled1 locationNCT06742463
Recruiting
Phase 1Phase 2

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06735495
Recruiting

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Leukemia/LymphomaCutaneous T Cell LymphomaATLL
Kyowa Kirin, Inc.150 enrolled1 locationNCT04014374
Recruiting
Phase 1Phase 2

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06503094
Recruiting
Not Applicable

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T Lymphoblastic Leukemia/Lymphoma
Shenzhen University General Hospital20 enrolled1 locationNCT05620680